TNBC roadmap: from 'nothing to target' to ADC + immunotherapy first line

Overview

1. 2000-2015historic

   Chemotherapy only

   Basal-like subtype defined (2000); TNBC named by exclusion (2007). Anthracycline-taxane chemotherapy; carboplatin added (2014). Median metastatic OS was about 13-18 months, and EGFR, VEGF, and PARP inhibitor (iniparib) trials failed repeatedly.

   Hide era· 2 records

   ⟳CarboplatinPlatinum agents
2. 2018-2020historic

   Immunotherapy and PARP arrive

   The pivotal trials are IMpassion130 (atezolizumab, later withdrawn), OlympiAD/EMBRACA (PARP inhibitors in gBRCA), KEYNOTE-355 (pembrolizumab CPS ≥10 first line), ASCENT (sacituzumab govitecan).

   Show era· 5 records
3. 2021-2022historic

   Curative setting transformed

   KEYNOTE-522 makes chemo-immunotherapy the standard for stage II-III; OlympiA adds adjuvant olaparib for gBRCA. DESTINY-Breast04 makes HER2-low TNBC eligible for T-DXd.

   Show era· 3 records
4. 2024-2026current

   ADCs move to first line; bispecific ADC succeeds

   KEYNOTE-522 OS benefit confirmed. ASCENT-03/04 and TROPION-Breast02 read out positive, bringing first-line approvals for sacituzumab govitecan and Dato-DXd (2026). Iza-bren posts a positive phase 3 (2026). TIL-based de-escalation in stage I gains evidence.

   Hide era· 5 records

   ASCENT-03ASCENT-04 / KEYNOTE-D19TROPION-Breast02BL-B01D1-307Tumour-infiltrating lymphocytes (TILs)

   Trial outcomes

   ASCENT-03

   In plain words

   What these results mean for people, not percentages

   558 randomised

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 9.7 vs 6.9 months with Sacituzumab govitecan compared with Chemotherapy (TPC); about 2.8 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62, likely range 0.5 to 0.77).

   Objective response rateresponse endpoint

   • 48 vs 44 out of 100 had their tumour shrink with Sacituzumab govitecan compared with Chemotherapy (TPC); 4 more per 100.
   • Roughly one extra person helped for every 25 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.

   Overall survivalsurvival endpoint

   • Numbers are not recorded here for this endpoint. Sacituzumab govitecan: Immature at the primary analysis; crossover to sacituzumab permitted on progression.; Chemotherapy (TPC).

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

   ASCENT-04 / KEYNOTE-D19

   In plain words

   What these results mean for people, not percentages

   443 enrolled

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 11.2 vs 7.8 months with Sacituzumab govitecan + pembrolizumab compared with Chemotherapy + pembrolizumab; about 3.4 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 35 percent lower chance of the event at any given time (hazard ratio 0.65, likely range 0.51 to 0.84).

   Objective response rateresponse endpoint

   • 60 vs 53 out of 100 had their tumour shrink with Sacituzumab govitecan + pembrolizumab compared with Chemotherapy + pembrolizumab; 7 more per 100.
   • Roughly one extra person helped for every 14 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.

   Overall survivalsurvival endpoint

   • Numbers are not recorded here for this endpoint. Sacituzumab govitecan + pembrolizumab: Immature; PFS2 favoured the ADC arm in the ASCO 2026 update.; Chemotherapy + pembrolizumab.

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

   TROPION-Breast02

   In plain words

   What these results mean for people, not percentages

   644 enrolled

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 10.8 vs 5.6 months with Datopotamab deruxtecan compared with Chemotherapy (ICC); about 5.2 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 43 percent lower chance of the event at any given time (hazard ratio 0.57, likely range 0.47 to 0.69).

   Overall survivalprimarysurvival endpoint

   • Median 23.7 vs 18.7 months with Datopotamab deruxtecan compared with Chemotherapy (ICC); about 5 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 21 percent lower chance of the event at any given time (hazard ratio 0.79, likely range 0.64 to 0.98).

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

   BL-B01D1-307

   In plain words

   What these results mean for people, not percentages

   418 enrolled

   Progression-free survival (BICR)primarysurrogate endpoint

   • Median 8.5 vs 3.1 months with Izalontamab brengitecan compared with Chemotherapy (TPC); about 5.4 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 71 percent lower chance of the event at any given time (hazard ratio 0.29, likely range 0.22 to 0.38).

   Overall survival (interim, median follow-up 11 months)primarysurvival endpoint

   • Median 15.9 vs 12.5 months with Izalontamab brengitecan compared with Chemotherapy (TPC); about 3.4 months longer for half the group.
   • A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
   • Put another way, the treated group had about 40 percent lower chance of the event at any given time (hazard ratio 0.6, likely range 0.42 to 0.85).

   Confirmed objective response rate (BICR)response endpoint

   • 51.7 vs 20.5 out of 100 had their tumour shrink with Izalontamab brengitecan compared with Chemotherapy (TPC); 31.2 more per 100.
   • Roughly one extra person helped for every 3 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.

   Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.

   Pictograms, table and sources on the trial page

5. 2026-2029emerging

   Next: residual disease, de-escalation, selection

   OptimICE-pCR (omit adjuvant pembrolizumab after pCR), SCARLET (drop anthracycline), ctDNA-guided escalation for RCB II-III, ADCs in the post-neoadjuvant setting, sac-TMT and TROPION-Breast05 first-line readouts, IZABRIGHT-Breast01, TROP2 PET.

   Show era· 7 records
6. 2029+speculative25% to 50%likely

   Speculative: cure for most, control for the rest

   Neoadjuvant ADC + IO replacing anthracyclines; personalised vaccines in the adjuvant setting for high-risk residual disease; payload-switching ADC algorithms guided by PET and ctDNA; mesenchymal-subtype-specific therapy; brain-penetrant ADCs.

   Show era· 4 records

Every era's records, trial outcomes and papers, and every watch item, as JSON.